<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H6161C3709B9E464DB8D7AE4DA0173192" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 4438 IH: John W. Walsh Alpha-1 Home Infusion Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-06-30</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 4438</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230630">June 30, 2023</action-date><action-desc><sponsor name-id="S000168">Ms. Salazar</sponsor> (for herself, <cosponsor name-id="P000597">Ms. Pingree</cosponsor>, <cosponsor name-id="P000599">Mr. Posey</cosponsor>, <cosponsor name-id="T000469">Mr. Tonko</cosponsor>, <cosponsor name-id="W000797">Ms. Wasserman Schultz</cosponsor>, <cosponsor name-id="K000375">Mr. Keating</cosponsor>, <cosponsor name-id="P000613">Mr. Panetta</cosponsor>, <cosponsor name-id="C001078">Mr. Connolly</cosponsor>, and <cosponsor name-id="H001038">Mr. Higgins of New York</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII of the Social Security Act to provide for coverage and payment of Alpha-1 Antitrypsin Deficiency Disorder treatment under part B of such title, and for other purposes.</official-title></form><legis-body id="H036864D28135482BAA7604650C741FCB" style="OLC"><section id="HEBC8BA1CFCF0428C84CD374FF6F68DF5" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>John W. Walsh Alpha-1 Home Infusion Act of 2023</short-title></quote>.</text></section><section id="H5C5582D55CBF4137A0E30D41419DEDE9"><enum>2.</enum><header>Medicare coverage of Alpha-1 Antitrypsin Disorder treatment</header><subsection id="HB701892961434F148238CBA25FFB9240"><enum>(a)</enum><header>In general</header><text>Section 1861 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x</external-xref>) is amended—</text><paragraph id="HF16E31C83CF341F88CD7E06829499AD1"><enum>(1)</enum><text>in subsection (s)(2)—</text><subparagraph id="HB88F231FDC7741C8952F6C260AE34A9D"><enum>(A)</enum><text>by striking <quote>and</quote> at the end of subparagraph (II);</text></subparagraph><subparagraph id="HC46A141F0B77483D8C9D75558833713B"><enum>(B)</enum><text>by inserting <quote>and</quote> at the end of subparagraph (JJ); and</text></subparagraph><subparagraph id="HEFC6A4BA0FE04D0F88B1070331D037B0"><enum>(C)</enum><text>by inserting at the end the following new subparagraph:</text><quoted-block id="HD6C7AB4D6A55459786D32DF6DBD99B24" style="OLC"><subparagraph id="HE2AC68F3777046E58C6C67D8419987A4"><enum>(KK)</enum><text display-inline="yes-display-inline">Alpha-1 Antitrypsin Deficiency Disorder treatment (as defined in subsection (nnn));</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H4B85753538BF48EAA822456B58FBB64F"><enum>(2)</enum><text>by adding at the end the following new subsection:</text><quoted-block id="HBD6D1588336840FC90DB81DD57EEA968" style="OLC"><subsection id="H1D12873524E04101A4988810C706FC00"><enum>(nnn)</enum><header>Alpha-1 Antitrypsin Deficiency Disorder treatment</header><paragraph commented="no" display-inline="yes-display-inline" id="H9905657DFCC9431E936D9F2ED02D9C6B"><enum>(1)</enum><text display-inline="yes-display-inline">The term <quote>Alpha-1 Antitrypsin Deficiency Disorder treatment</quote> means augmentation therapy (as defined in paragraph (2)(C)) furnished by qualified home infusion therapy suppliers (as defined in paragraph (2)(D)) which are furnished in the individual’s home (as defined in paragraph (2)(B)) to an individual—</text><subparagraph id="HF69E9AA2C3554DAE8652B41FB7BCDB48" indent="up1"><enum>(A)</enum><text>who is under the care of an applicable provider;</text></subparagraph><subparagraph id="H9AC26FC3E3A04302AD325332ABBB7835" indent="up1"><enum>(B)</enum><text>who is enrolled under both parts A and B of this title, and is not enrolled in an MA plan under part C of such title; and</text></subparagraph><subparagraph id="HFF86B6AD285748B893939DE046E002E7" indent="up1"><enum>(C)</enum><text display-inline="yes-display-inline">who requires augmentation therapy (as defined in paragraph (2)(C)).</text></subparagraph></paragraph><paragraph id="H33D9946C05974651965087ADF3240DF1" indent="up1"><enum>(2)</enum><text>For purposes of this subsection:</text><subparagraph id="H63F6D59C96B34DBFBFB4B5309152B5D7"><enum>(A)</enum><text>The term <quote>applicable provider</quote> means—</text><clause id="H49734C89FCAA4C1D9A6473F9AA124914"><enum>(i)</enum><text>a physician;</text></clause><clause id="H4709FE1783594A38BBADB6144572C412"><enum>(ii)</enum><text>a nurse practitioner; and</text></clause><clause id="H997474C147174909B51271550887E3C1"><enum>(iii)</enum><text>a physician assistant.</text></clause></subparagraph><subparagraph id="H17BA1DB6D0244B4F8BB092A450D7A2A0"><enum>(B)</enum><text>The term <quote>home</quote> means a place of residence used as the home of an individual (as defined for purposes of subsection (n)).</text></subparagraph><subparagraph id="H625E156CF870430FAA5E08F211DD3847"><enum>(C)</enum><text display-inline="yes-display-inline">The term <quote>augmentation therapy</quote> means an Alpha-1 Proteinase Inhibitor indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of Alpha-1 Antitrypsin.</text></subparagraph><subparagraph id="H99E4CDD3B75C478E9201EB3BE332101D"><enum>(D)</enum><text>The term <quote>qualified home infusion therapy supplier</quote> has the meaning given such term in subsection (iii)(3)(D)(i).</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H2EA30C81FBF34874A7709EA6E51CF2FF"><enum>(b)</enum><header>Payment for intravenous administration kits and nursing services for Alpha-1 Antitrypsin Deficiency Disorder treatment</header><text>Section 1834 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m</external-xref>) is amended by adding at the end the following new subsection:</text><quoted-block id="H76DA7DA81A284656B92FB7AEE110D1C8" style="OLC"><subsection id="H54C23A9B93964F54A325E55C29ADB59D"><enum>(aa)</enum><header>Payment for intravenous administration kits and nursing services for Alpha-1 Antitrypsin Deficiency Disorder treatment</header><text display-inline="yes-display-inline">The Secretary shall implement a payment system under which payment is made under this title to a qualified home infusion therapy supplier (as defined in section 1861(nnn)(3)(D)) for intravenous administration kits and nursing services for up to 2 hours of care by a qualified home infusion therapy supplier in coordination with the furnishing of augmentation therapy (as defined in section 1861(nnn)(2)(C)).</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H40F810BB2A1A4DBFB24FC7EA12344B6F"><enum>(c)</enum><header>Conforming amendments</header><paragraph id="H227C4008D565400699EB158175EAB524"><enum>(1)</enum><header>Payment reference</header><text>Section 1833(a)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">42 U.S.C. 1395l(a)(1)</external-xref>) is amended—</text><subparagraph id="H4615BF0BEBF7437AA7149A17C6383901"><enum>(A)</enum><text>by striking <quote>and</quote> before <quote>(HH)</quote>; and</text></subparagraph><subparagraph id="H7FF9EA54AC354BE297BF2DA50E2BE4B5"><enum>(B)</enum><text>by inserting before the semicolon at the end the following: <quote>, and (II) with respect to intravenous administration kits and nursing services described in section 1834(aa) for Alpha-1 Antitrypsin Disorder treatment (as defined in subsection (nnn)(1)), the amount paid for such kits and services shall be an amount equal to 80 percent of the lesser of the actual charge for the services or the amount determined under section 1834(aa)</quote>.</text></subparagraph></paragraph><paragraph id="HBF96CEAA86A64D41B10276C3B6316DDD"><enum>(2)</enum><header>Direct payment</header><text>The first sentence of section 1842(b)(6) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395u">42 U.S.C. 1395u(b)(6)</external-xref>) is amended—</text><subparagraph id="H9B24EE7E74B54E92A0660A1D2F80930B"><enum>(A)</enum><text>by striking <quote>and</quote> before <quote>(J)</quote>; and</text></subparagraph><subparagraph id="H85BF68DBBDD44971AE5F2DA1F0A182C2"><enum>(B)</enum><text>by inserting before the period at the end the following: <quote>, and (K) in the case of intravenous administration kits and nursing services described in section 1834(aa), payment shall be made to the qualified home infusion therapy supplier (as defined in section 1861(nnn)(2)(D))</quote>.</text></subparagraph></paragraph><paragraph id="H42F3A26C7A5D4AC2AAAFB211DD49ACF5"><enum>(3)</enum><header>Exclusion from home health services</header><text>Section 1861(m) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(m)</external-xref>) is amended, in the first sentence, by inserting the following before the period at the end: <quote>and intravenous administration kits and nursing services described in section 1834(aa) for Alpha-1 Antitrypsin Deficiency Disorder treatment (as defined in subsection (nnn)(1))</quote>.</text></paragraph></subsection><subsection id="HC2F705CAE8DA4022A840B7E3A7351559"><enum>(d)</enum><header>Effective date</header><text>The amendments made by this section shall apply to items and services furnished on or after January 1, 2025.</text></subsection></section></legis-body></bill> 

